ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
34 announcements
Niva Bupa Health Insurance received credit ratings from AM Best, including a Financial Strength Rating of A- and Long-Term Issuer Credit Rating of a-.
Niva Bupa Health Insurance announced that Mr. Vikas Jain transitioned to Chief Transformation Officer, while Mr. Karan Bhatia was appointed as the new Chief Investment Officer.
Niva Bupa received an ESG rating of '67 Leader' for FY24-25 and FY25-26 from Niche99. The rating was assigned independently by the SEBI-registered provider without company engagement.
Niva Bupa Health Insurance allotted 4,11,000 equity shares to employees under its ESOP schemes, increasing the company's total paid-up share capital.
Niva Bupa Health Insurance received credit rating actions from ICRA, reaffirming its Issuer Rating and assigning a rating to its proposed ₹500 crore subordinated debt issue.
IRDAI warned Niva Bupa for non-compliance with Expense of Management limits. The regulator prohibited the company from opening new business locations for six months.
Niva Bupa Health Insurance held its 18th Annual General Meeting on August 12, 2026, to discuss business performance and approve key director appointments and remunerations.
Niva Bupa Health Insurance Company Limited received IRDAI approval for appointing Mr. Ashwani Bhatia as Chairperson. The appointment is effective retrospectively from June 03, 2026.
Niva Bupa reported strong Q1 FY27 results with 31.7% reported growth and PAT improving to INR 137.8 crores. Management focused on retail health expansion and transition to Ind AS accounting.
Niva Bupa Health Insurance's board approved raising up to ₹500 Crore via debt securities. A Debt Raising Committee was formed to finalize terms.
Niva Bupa Health Insurance reported a 93% YoY growth in PAT to ₹138 crore, with a Gross Written Premium of ₹2,150 crore for Q1 FY2026.
Niva Bupa reported strong Q1’FY2027 performance with GWP growing 31.7% and PAT nearly doubling to ₹137.8 crore, driven by retail health market share expansion to 11.1% and improved underwriting discipline.
Niva Bupa Health Insurance Company Ltd reported revenue from operations of ₹2,274 Cr (+28.6% YoY) and net profit of ₹137.8 Cr (+93.0% YoY) for Q1 FY27.
Niva Bupa Health Insurance will hold a board meeting on July 30, 2026, to consider quarterly financial results and potential debt-based fund raising.
Niva Bupa Health Insurance filed its quarterly shareholding pattern for the period ended June 30, 2026. The filing discloses changes within the promoter group structure.
Niva Bupa Health Insurance Company Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's ESG and governance frameworks.
Niva Bupa Health Insurance scheduled its 18th AGM for August 12, 2026. The meeting will address financial statements, auditor appointments, and director remunerations via video conferencing.
ICRA Limited assigned an issuer rating of [ICRA]AAA(Stable) to Niva Bupa Health Insurance. This top-tier investment grade rating reflects strong creditworthiness and stable outlook.
Niva Bupa received a ₹22.12 Crore GST refund sanction order. The tax litigation, concerning input tax credit from 2017-2022, was resolved in the company's favor.
Niva Bupa appointed Mr. Ashwani Bhatia as Chairperson following Mr. Milind Barve's resignation due to health reasons. The leadership transition ensures continuity in board governance.
Niva Bupa Health Insurance filed its Annual Secretarial Compliance Report for FY2025-26. The auditor confirmed compliance with SEBI regulations, noting no fresh penalties during the review period.
Niva Bupa reported strong Q4 FY26 results with PAT growing 90% YoY to ₹366cr for the full year. Strategy focuses on multichannel distribution and digital growth.
Niva Bupa Health Insurance reported FY26 Net Profit of ₹13,078 lakhs on Gross Premiums of ₹8,58,592 lakhs. Focus remains on retail health and solvency management.
Niva Bupa elevated Ankur Kharbanda to Deputy CEO while Ms. Penelope Dudley and Mr. Carlos Jaureguizar Ruiz-Jarabo resigned. The board also approved 12,251,268 ESOP grants.
Niva Bupa reported ₹366 Crore PAT for FY26, representing 80% year-on-year growth. Gross Written Premium reached ₹8,586 Crore as market share improved to 10.1%.
Niva Bupa achieved 27.4% GWP growth to ₹9,433 Cr and 80.4% PAT growth to ₹366.1 Cr (IFRS) in FY26, driven by retail health expansion and improved efficiencies.
Niva Bupa reported stellar FY26 performance with GWP of ₹9,433 crore and PAT of ₹366 crore (IFRS). Strategy focuses on multi-channel distribution, digital automation, and LTV-based underwriting to drive profitability.
Niva Bupa Health Insurance Company Ltd reported revenue from operations of ₹2,302 Cr (+37.7% YoY) and net profit of ₹345.1 Cr (+67.4% YoY) for Q4 FY26.
Niva Bupa Health Insurance reported a net profit of ₹130.78 Crore for FY26. The board approved these results following its meeting on May 08, 2026.
Niva Bupa Health Insurance Company Limited will hold a Board meeting on May 08, 2026, to approve audited financial results for the quarter and year ended March 31, 2026. The company's trading window remains closed until May 10, 2026.